While widespread adoption of 3D printing within the bio/pharma industry needs to overcome some key hurdles, its potential for the future is tremendous, emphasizes Tom Sellig from Adare Pharma Solutions.

Bio/pharma companies are turning their focus to Indian CDMOs to build resilience into their KSM and API supply chains and to help with complex payloads, according to Yann D’Hervé from Cohance.

In collaboration with A.forall and IMGA, Nanoform has formed a new subsidiary aimed at outlicensing Nanoencorafenib as an attractive patient-centric lifecycle management opportunity or value-added generic medicine opportunity.

Bio/pharma companies are adjusting their strategies to cope with a variety of industry trends and are seeking out partners that can not only provide them with capacity but also support them through their innovation journey.

The Big Pharma companies have voluntarily agreed to a range of measures to reduce the cost of medicines for American patients while also preserving the biopharmaceutical innovation ecosystem of the U.S.

Regeneron’s investigational gene therapy, DB-OTO, has been found to provide meaningful improvements in hearing for nearly all of the participants in the CHORD clinical trial.

The companies have entered into a definitive agreement for the acquisition, which includes an investigational immunotherapy preclinical candidate and a proprietary RNA modular platform.

Located in Stein, Switzerland, the new GMP licensed line will enable the company to provide integrated, end-to-end solutions for the whole biologics and bioconjugation value chain.

As demand for increasingly complex biologics grows, technological advances and innovative approaches are enabling companies to progress their biomanufacturing efforts.

Through the strategic acquisition of a facility from WuXi Biologics based in Germany, Terumo has strengthened its ability to serve both domestic and international pharmaceutical companies.

The Polish company debuts as a European biologics CDMO, offering services from accelerated development through to commercialization using advanced digital tools and mirrored GMP-certified sites.

Innovator companies are increasingly engaging with outsourcing partners in efforts to improve cost and time efficiencies across the complete drug development lifecycle.

Luke Miels, the company’s current Chief Commercial Officer, has been appointed as the new CEO, signaling the company’s next phase after Dame Emma Walmsley’s era of strategic growth and innovation.

While the levies seem steep the impact on industry may be less severe than expected as many companies have a presence or are planning works for manufacturing facilities within the U.S., making them exempt from the tariffs.

Through the purchase the contract packaging organization will add 160,000 sq. ft. of manufacturing and warehouse facilities in Florida and will expand its capabilities and market segments.

Using its fully-connected continuous manufacturing technology, the CDMO has developed and scaled up pertuzumab to commercial launch readiness for the Indian market.

During CPHI Frankfurt, Sanner Group will unveil expanded CDMO capabilities and innovations in moisture management, with a joint presentation with Pfizer experts on next-generation drug delivery design.

Led by researchers at the University of Liverpool, a team of international scientists have discovered a new, potent class of antibiotics that will help in the fight against antimicrobial resistance.

Winners for each of the 14 categories will be chosen from the selected finalists and revealed during the CPHI Celebration event at CPHI Frankfurt on October 28, 2025.  

At the 15th Drug Delivery & Formulation Summit in Boston, Nanoform unveiled proof‑of‑concept data demonstrating new approaches to biologic drug delivery.